 |
|
Washington University scientists first to sequence genome of cancer patient
November 06, 2008For the first time, scientists have decoded the complete DNA of a cancer patient and traced her disease - acute myelogenous leukemia - to its genetic roots. A large research team at the Genome Sequencing Center and the Siteman Cancer Center at Washington University School of Medicine in St. Louis sequenced the genome of the patient - a woman in her 50s who ultimately died of her disease - and the genome of her leukemia cells, to identify genetic changes unique to her cancer.
The study is reported in the Nov. 6 issue of the journal Nature.
The pioneering work sets the stage for using a more comprehensive, genome-wide approach to unravel the genetic basis of cancer. "Our work demonstrates the power of sequencing entire genomes to discover novel cancer-related mutations," says senior author Richard K. Wilson, Ph.D., director of Washington University's Genome Sequencing Center. "A genome-wide understanding of cancer, which is now possible with faster, less expensive DNA sequencing technology, is the foundation for developing more effective ways to diagnose and treat cancer."
The researchers discovered just 10 genetic mutations in the patient's tumor DNA that appeared to be relevant to her disease; eight of the mutations were rare and occurred in genes that had never been linked to AML. They also showed that virtually every cell in the tumor sample had nine of the mutations, and that the single genetic alteration that occurred less frequently was likely the last to be acquired. The scientists suspect that all the mutations were important to the patient's cancer.
Like most cancers, AML - a cancer of blood-forming cells in the bone marrow - arises from mutations that accumulate in people's DNA over the course of their lives. However, little is known about the precise nature of those changes and how they disrupt biological pathways to cause the uncontrolled cell growth that is the hallmark of cancer.
Previous efforts to decode individual human genomes have looked at common points of DNA variation that may be relevant for disease risk. What's striking about the new research is that the scientists were able to sift through the 3 billion pairs of chemical bases that make up the human genome to pull out the mutations that contributed to the patient's cancer.
"Until now, no one has sequenced a patient's genome to find all the mutations that are unique to that person's disease," says lead author Timothy Ley, M.D., a hematologist and the Alan A. and Edith L. Wolff Professor of Medicine. "We didn't know what we would find, but we felt that the answers to why this patient had AML had to be embedded in her DNA."
To date, scientists involved in large-scale genetic studies of cancer have not gone so far as to do a full side-by-side comparison of the genomes of normal cells and tumor cells from the same patient. Rather, most earlier studies have involved the sequencing of genes with known or suspected relationships to cancer, a method that likely misses key mutations.
"The determination of the first complete DNA sequence of a human cancer genome, and its comparison to normal tissues of the same individual, is a true landmark in cancer research," says geneticist Francis Collins, M.D., Ph.D., former director of the National Human Genome Research Institute. "In the past, cancer researchers have been 'looking under the lamppost' to find the causes of malignancy - but now the team from Washington University has lit up the whole street. This achievement ushers in a new era of comprehensive understanding of the fundamental nature of cancer, and offers great promise for the development of powerful new approaches to diagnosis, prevention and treatment."
An estimated 13,000 cases of AML will be diagnosed in the United States this year, and some 8,800 will die of the disease. It occurs most often among those age 60 or older and becomes more difficult to treat as patients age. According to the American Cancer Society, the five-year survival rate for AML is 21 percent.
Despite advances in the genetic understanding of many cancers, scientists have learned very little about the genetic basis of AML. "After years of genetic studies of AML looking at genes of interest, we were getting no closer to uncovering the molecular underpinnings of the disease," Ley says. "We felt that with new genome sequencing technology, now was the time to take a whole-genome approach."
Based on genetic testing with traditional methods at the study's outset, the patient was known to have two mutations that are common among AML patients, an indicator she had a typical subtype of the disease, and one of the many reasons why her genome was selected for sequencing.
The researchers sequenced the patient's full genome, meaning DNA from both sets of chromosomes, using genetic material obtained from a skin sample. This gave the scientists a reference DNA sequence to which they could compare genetic alterations in the patient's tumor cells, taken from a bone marrow sample that was comprised only of tumor cells. Both samples were obtained before the patient received cancer treatment, which can further damage DNA.
The scientists then looked for genetic differences - points of single base changes in the DNA - in the patient's tumor genome compared with her normal genome. Of the nearly 2.7 million single nucleotide variants in the patient's tumor genome, almost 98 percent also were detected in DNA from the patient's skin sample, thus narrowing the number of variants that required further study to about 60,000.
Using sophisticated software and analytical tools, some of which the researchers developed specifically for this project, they identified the 10 mutations (including the two previously known genetic mutations that are common to her leukemia subtype but do not directly cause the disease) by looking for single base DNA changes that altered the instructions for making proteins.
Of the eight novel mutations discovered, three were found in genes that normally act to suppress tumor growth. One of these mutations is in the PTPRT tyrosine phosphatase gene, which is frequently altered in colon cancer.
Four other mutated genes appear to be involved in molecular pathways that promote cancer growth. In particular, one mutation was found in a gene family that also is expressed in embryonic stem cells and may be involved with cell self-renewal. Interestingly, the researchers note, self-renewal is thought to be an essential feature of leukemia cells.
Another gene alteration appears to affect the transport of drugs into the cell, and may have contributed to the patient's chemotherapy resistance.
"We're still analyzing the patient's non-coding DNA and expect to find a number of additional relevant mutations in this portion of the genome," says Elaine Mardis, Ph.D., co-lead author of the study and co-director of the Genome Sequencing Center. "But the role of these non-coding mutations will be more of a challenge to elucidate because we do not yet fully understand the function of this part of the genome."
The team also looked to see if the eight novel mutations in the patient's tumor genome also occurred in the DNA of tumor samples from 187 additional AML patients. None of those tumors had any of the eight mutations.
"This suggests that there is a tremendous amount of genetic diversity in cancer, even in this one disease," Wilson says. "There are probably many, many ways to mutate a small number of genes to get the same result, and we're only looking at the tip of the iceberg in terms of identifying the combinations of genetic mutations that can lead to AML."
Based on their current understanding of cancer, the researchers suspect that the mutations occurred sequentially. The first mutation gave the cell a slight tendency toward cancer, and then one by one, the other genetic alterations were acquired, with each contributing something to the cancer. One mutation, in the FLT3 gene, was not present in all of the tumor cells, and they suspect that it was the last one to occur. "The final mutation may represent a tipping point that causes the cancer cells to become more dangerous," Ley says.
The team is now sequencing the genomes of additional patients with AML, and they are also planning to expand the whole-genome approach to breast and lung cancers.
This type of approach is exactly what is needed to understand the genetic basis of cancer, an essential first step to developing targeted therapies, says Brian Druker, M.D., whose research helped identify the targeted drug Gleevec as a promising therapy for chronic myelogenous leukemia. Druker, the director of the Oregon Health & Science University Cancer Institute and a Howard Hughes Medical Institute investigator, was not involved in the current study.
"This tour-de-force effort identified a small number of mutations in genes that no one predicted, and their uniqueness for this patient begins to give us a glimmer of the genetic complexity and diversity of this disease," he says. "Although this information doesn't yet tell us how to treat patients, it is a critical first step along that path. It sets the stage for large scale sequencing of cancer genomes and unraveling the mystery of cancer."
Washington University School of Medicine in St. Louis
The researchers discovered just 10 genetic mutations in the patient's tumor DNA that appeared to be relevant to her disease; eight of the mutations were rare and occurred in genes that had never been linked to AML. They also showed that virtually every cell in the tumor sample had nine of the mutations, and that the single genetic alteration that occurred less frequently was likely the last to be acquired. The scientists suspect that all the mutations were important to the patient's cancer.
Like most cancers, AML - a cancer of blood-forming cells in the bone marrow - arises from mutations that accumulate in people's DNA over the course of their lives. However, little is known about the precise nature of those changes and how they disrupt biological pathways to cause the uncontrolled cell growth that is the hallmark of cancer.
Previous efforts to decode individual human genomes have looked at common points of DNA variation that may be relevant for disease risk. What's striking about the new research is that the scientists were able to sift through the 3 billion pairs of chemical bases that make up the human genome to pull out the mutations that contributed to the patient's cancer.
"Until now, no one has sequenced a patient's genome to find all the mutations that are unique to that person's disease," says lead author Timothy Ley, M.D., a hematologist and the Alan A. and Edith L. Wolff Professor of Medicine. "We didn't know what we would find, but we felt that the answers to why this patient had AML had to be embedded in her DNA."
To date, scientists involved in large-scale genetic studies of cancer have not gone so far as to do a full side-by-side comparison of the genomes of normal cells and tumor cells from the same patient. Rather, most earlier studies have involved the sequencing of genes with known or suspected relationships to cancer, a method that likely misses key mutations.
"The determination of the first complete DNA sequence of a human cancer genome, and its comparison to normal tissues of the same individual, is a true landmark in cancer research," says geneticist Francis Collins, M.D., Ph.D., former director of the National Human Genome Research Institute. "In the past, cancer researchers have been 'looking under the lamppost' to find the causes of malignancy - but now the team from Washington University has lit up the whole street. This achievement ushers in a new era of comprehensive understanding of the fundamental nature of cancer, and offers great promise for the development of powerful new approaches to diagnosis, prevention and treatment."
An estimated 13,000 cases of AML will be diagnosed in the United States this year, and some 8,800 will die of the disease. It occurs most often among those age 60 or older and becomes more difficult to treat as patients age. According to the American Cancer Society, the five-year survival rate for AML is 21 percent.
Despite advances in the genetic understanding of many cancers, scientists have learned very little about the genetic basis of AML. "After years of genetic studies of AML looking at genes of interest, we were getting no closer to uncovering the molecular underpinnings of the disease," Ley says. "We felt that with new genome sequencing technology, now was the time to take a whole-genome approach."
Based on genetic testing with traditional methods at the study's outset, the patient was known to have two mutations that are common among AML patients, an indicator she had a typical subtype of the disease, and one of the many reasons why her genome was selected for sequencing.
The researchers sequenced the patient's full genome, meaning DNA from both sets of chromosomes, using genetic material obtained from a skin sample. This gave the scientists a reference DNA sequence to which they could compare genetic alterations in the patient's tumor cells, taken from a bone marrow sample that was comprised only of tumor cells. Both samples were obtained before the patient received cancer treatment, which can further damage DNA.
The scientists then looked for genetic differences - points of single base changes in the DNA - in the patient's tumor genome compared with her normal genome. Of the nearly 2.7 million single nucleotide variants in the patient's tumor genome, almost 98 percent also were detected in DNA from the patient's skin sample, thus narrowing the number of variants that required further study to about 60,000.
Using sophisticated software and analytical tools, some of which the researchers developed specifically for this project, they identified the 10 mutations (including the two previously known genetic mutations that are common to her leukemia subtype but do not directly cause the disease) by looking for single base DNA changes that altered the instructions for making proteins.
Of the eight novel mutations discovered, three were found in genes that normally act to suppress tumor growth. One of these mutations is in the PTPRT tyrosine phosphatase gene, which is frequently altered in colon cancer.
Four other mutated genes appear to be involved in molecular pathways that promote cancer growth. In particular, one mutation was found in a gene family that also is expressed in embryonic stem cells and may be involved with cell self-renewal. Interestingly, the researchers note, self-renewal is thought to be an essential feature of leukemia cells.
Another gene alteration appears to affect the transport of drugs into the cell, and may have contributed to the patient's chemotherapy resistance.
"We're still analyzing the patient's non-coding DNA and expect to find a number of additional relevant mutations in this portion of the genome," says Elaine Mardis, Ph.D., co-lead author of the study and co-director of the Genome Sequencing Center. "But the role of these non-coding mutations will be more of a challenge to elucidate because we do not yet fully understand the function of this part of the genome."
The team also looked to see if the eight novel mutations in the patient's tumor genome also occurred in the DNA of tumor samples from 187 additional AML patients. None of those tumors had any of the eight mutations.
"This suggests that there is a tremendous amount of genetic diversity in cancer, even in this one disease," Wilson says. "There are probably many, many ways to mutate a small number of genes to get the same result, and we're only looking at the tip of the iceberg in terms of identifying the combinations of genetic mutations that can lead to AML."
Based on their current understanding of cancer, the researchers suspect that the mutations occurred sequentially. The first mutation gave the cell a slight tendency toward cancer, and then one by one, the other genetic alterations were acquired, with each contributing something to the cancer. One mutation, in the FLT3 gene, was not present in all of the tumor cells, and they suspect that it was the last one to occur. "The final mutation may represent a tipping point that causes the cancer cells to become more dangerous," Ley says.
The team is now sequencing the genomes of additional patients with AML, and they are also planning to expand the whole-genome approach to breast and lung cancers.
This type of approach is exactly what is needed to understand the genetic basis of cancer, an essential first step to developing targeted therapies, says Brian Druker, M.D., whose research helped identify the targeted drug Gleevec as a promising therapy for chronic myelogenous leukemia. Druker, the director of the Oregon Health & Science University Cancer Institute and a Howard Hughes Medical Institute investigator, was not involved in the current study.
"This tour-de-force effort identified a small number of mutations in genes that no one predicted, and their uniqueness for this patient begins to give us a glimmer of the genetic complexity and diversity of this disease," he says. "Although this information doesn't yet tell us how to treat patients, it is a critical first step along that path. It sets the stage for large scale sequencing of cancer genomes and unraveling the mystery of cancer."
Washington University School of Medicine in St. Louis
Genome Sequencing Current Events and Genome Sequencing News RSSScientists at UA, collaborating institutions decode maize genome
Scientists from the University of Arizona led by Arizona Genomics Institute director Rod A. Wing and from collaborating institutions have deciphered the complete genetic code of the maize plant for the first time.
UCSD discovery allows scientists for the first time to experimentally annotate genomes
Over the last 20 years, the sequencing of the human genome, along with related organisms, has represented one of the largest scientific endeavors in the history of mankind.
Standards for a new genomic era
A team of geneticists at Los Alamos National Laboratory, together with a consortium of international researchers, has recently proposed a set of standards designed to elucidate the quality of publicly available genetic sequencing information.
Establishing standard definitions for genome sequences
In 1996, researchers from major genome sequencing centers around the world convened on the island of Bermuda and defined a finished genome as a gapless sequence with a nucleotide error rate of one or less in 10,000 bases.
Draft potato genome based on unique potato variety
The Potato Genome Sequencing Consortium (PGSC), an international team of scientists from industry and academia in 14 countries, has released a draft sequence of the potato genome with the help of a Virginia Tech researcher.
MSU scientist helps map potato genome; move will improve crop yield
It's been cultivated for at least 7,000 years and spread from South America to grow on every continent except Antarctica. Now the humble potato has had its genome sequenced.
Study of huge numbers of genetic mutations point to oxidative stress as underlying cause
A study that tracked genetic mutations through the human equivalent of about 5,000 years has demonstrated for the first time that oxidative DNA damage is a primary cause of the process of mutation - the fuel for evolution but also a leading cause of aging, cancer and other diseases.
Faster, cheaper way to find disease genes in human genome passes initial test
University of Washington (UW) researchers have successfully developed a novel genome-analysis strategy for more rapid, lower cost discovery of possible gene-disease links.
CSHL scientists harness logic of 'Sudoku' math puzzle to vastly enhance genome-sequencing capability
A math-based game that has taken the world by storm with its ability to delight and puzzle may now be poised to revolutionize the fast-changing world of genome sequencing and the field of medical genetics.
Aluminum-oxide nanopore beats other materials for DNA analysis
Fast and affordable genome sequencing has moved a step closer with a new solid-state nanopore sensor being developed by researchers at the University of Illinois.
More Genome Sequencing Current Events and Genome Sequencing News Articles
 |
Genome Sequencing Technology and Algorithms by Sun Kim (Editor), Haixu Tang (Editor), Elaine R. Mardis (Editor) The 2003 completion of the Human Genome Project was just one step in the evolution of DNA sequencing. Now from a "who's who" of pioneers in the field comes the latest genome sequencing and assembly advances that are redefining the field. This trail-blazing book gives researchers, unparalleled access to state-of-the-art DNA sequencing technologies, new algorithmic sequence assembly techniques, and emerging methods for both resequencing and genome analysis that together form the most solid foundation possible for tackling experimental and computational challenges in the genome sciences today. Including critiques of existing techniques, this far-reaching resource offers researchers assistance in achieving more rapid and accurate DNA sequencing and developing the next generation of... |
 |
SciEd Sequencing the Human Genome; Dna Map Using Restcn Enzymes by Edvotek DNA Map Using Restcn Enzymes |
 |
Next-Generation Genome Sequencing: Towards Personalized Medicine by Michal Janitz (Editor) Written by leading experts from industry and academia, this comprehensive resource addresses recent developments in next generation DNA sequencing technology and their impact on genome research, drug discovery and health care. As such, it presents a detailed comparative analysis of commercially available platforms as well as insights into alternative, emerging sequencing techniques. In addition, the book not only covers the principles of DNA sequencing techniques but also social, ethical and commercial aspects, the concept of personalized medicine and a five-year perspective of DNA sequencing. |
 |
Charlie Rose (August 29, 2000) A rebroadcast of part two of the special edition series, "Mapping the Human Genome" that originally aired on June 20, 2000. Dr. Francis Collins, molecular geneticist and director of the National Center for Human Genome Research Institute at the National Institutes of Health, and his colleagues Judy Crabtree, Dr. Steven Lipkin, David Duggan and Dr. Olli-P. Kallioniemi, discuss the Human Genome Project. This product is manufactured on demand using DVD-R recordable media. Amazon.com's standard return policy will apply. |
|
Agaricus Bisporus Mushroom Genome Sequencing.(specialty mushrooms): An article from: Mushroom News by Richard W. Kerrigan (Author) This digital document is an article from Mushroom News, published by American Mushroom Institute on February 1, 2009. The length of the article is 614 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available immediately after purchase. You can view it with any web browser. Citation Details Title: Agaricus Bisporus Mushroom Genome Sequencing.(specialty mushrooms) Author: Richard W. Kerrigan Publication: Mushroom News (Magazine/Journal) Date: February 1, 2009 Publisher: American Mushroom Institute Volume: 57 Issue: 2 Page: 4(2) Distributed by Gale, a part of Cengage... | |
 |
Charlie Rose with Francis Collins, Steven Lipkin, David Duggan, Olli-P. Kallioniemi & Judy Crabtree (June 20, 2000) Part two of the special edition series, "Mapping the Human Genome." Dr. Francis Collins, molecular geneticist and director of the National Center for Human Genome Research Institute at the National Institutes of Health, and his colleagues Judy Crabtree, Dr. Steven Lipkin, David Duggan and Dr. Olli-P. Kallioniemi, discuss the Human Genome Project. This product is manufactured on demand using DVD-R recordable media. Amazon.com's standard return policy will apply. |
 |
Genome Mapping and Sequencing by Ian Dunham (Author) Written by experts in the field, this title provides a comprehensive source of information on DNA sequencing and mapping, the newest technologiy and procedures in areas such as radiation hybrid mapping, FISH and specialized sequencing techniques. It also covers genomic sequence software and sequence databases. This book is an essential guide for anyone involved in DNA sequencing and mapping. |
|
Rapid genome sequencing of RNA viruses.(DISPATCHES)(Disease/Disorder overview): An article from: Emerging Infectious Diseases by Tetsuya Mizutani (Author), Daiji Endoh (Author), Michiko Okamoto (Author), Kazuya Shirato (Author), Hiroyuki Shimizu (Author), Minetaro Arita (Author), Shuetsu Fukushi (Author), Masayuki Saijo (Author), Kouyi Sakai (Author), Chang Kweng Lim (Author), Mikako Ito (Author), Reiko Nerome (Author), Tomohiko Takasaki (Author), Koji Ishii (Author), Tetsuro Suzuki (Author) This digital document is an article from Emerging Infectious Diseases, published by Thomson Gale on February 1, 2007. The length of the article is 1571 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser. Citation Details Title: Rapid genome sequencing of RNA viruses.(DISPATCHES)(Disease/Disorder overview) Author: Tetsuya Mizutani Publication: Emerging Infectious Diseases (Magazine/Journal) Date: February 1, 2007 Publisher: Thomson Gale Volume: 13 Issue: 2 Page: 322(3) Article Type: Disease/Disorder overview Distributed by Thomson... | |
 |
Charlie Rose with Hamilton Smith, Francis Collins, Harold Varmus, Arnold Levine, James Watson, Nicholas Wade, William Haseltine, Arthur Caplan & J. Craig Venter (June 23, 2000) Episode five of the special series "Mapping the Human Genome." A panel of experts discusses the ethics and implications of the Human Genome Project. They are: Dr. Craig Venter, president of Celera Genomics; Dr. Hamilton Smith, in charge of creating a DNA library for Celera Genomics; Dr Francis Collins, molecular geneticist and director of the National Center for Human Genome Research Institute at the National Institutes of Health; Dr. Harold Varmus, president of Rockefeller University; Dr. James Watson, molecular biologist and co-discoverer of the double-helix structure of DNA; Nicholas Wade, science reporter for The New York Times; Dr. William Haseltine, chairman and CEO of Human Genome Sciences; and Dr. Arthur Caplan, director of the Center for Bioethics at the University of... |
 |
Mapping and Sequencing the Human Genome by Committee on Mapping and Sequencing the Human Genome (Author), National Research Council (Author) There is growing enthusiasm in the scientific community about the prospect of mapping and sequencing the human genome, a monumental project that will have far-reaching consequences for medicine, biology, technology, and other fields. But how will such an effort be organized and funded? How will we develop the new technologies that are needed? What new legal, social, and ethical questions will be raised? "Mapping and Sequencing the Human Genome" is a blueprint for this proposed project. The authors offer a highly readable explanation of the technical aspects of genetic mapping and sequencing, and they recommend specific interim and long-range research goals, organizational strategies, and funding levels. They also outline some of the legal and social questions that might arise and urge... |
| © 2009 BrightSurf.com |